(Q37833497)

24 August 2017

1 reference

title

Breast cancer in 2010: Novel targets and therapies for a personalized approach (English)

1 reference

24 August 2017

1 reference

Michaela J Higgins

1

1 reference

24 August 2017

José Baselga

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

Nature Reviews Clinical Oncology

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

65-66

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.217

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21278769

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.217

1 reference

release_hbe6mh44knc3tmfjbqqtyrmvbq

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hbe6mh44knc3tmfjbqqtyrmvbq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference